Anna's Deep Dives

_{Just facts, you think for yourself}

Biotech Startups in the Longevity Space

Profiles of High-Profile Startups (e.g., Altos Labs, Calico, Life Biosciences)

Altos Labs launched in 2022 with $3 billion in funding. The company focuses on cellular rejuvenation programming. Its goal is to reset aging cells and restore tissue function.

Altos Labs is based in California and has hubs in the UK and Japan. It employs leading scientists, including Nobel laureates Shinya Yamanaka and Jennifer Doudna. Yamanaka discovered the reprogramming factors that can revert adult cells to a youthful state.

The company invests heavily in basic science. Its work spans epigenetics, gene expression, and aging reversal. It also sponsors major scientific events like the Aging Research & Drug Discovery Meeting.

Calico Life Sciences was founded by Google in 2013. It has invested $1.5 billion to study the biology of aging and age-related diseases.

Calico partners with AbbVie in a $1 billion drug discovery deal. Together, they’ve launched over 20 early-stage research programs, focusing on cancer, neurodegeneration, and inflammation. It also uses machine learning to analyze health data and collaborates with Terray Therapeutics to develop small molecules.

Life Biosciences develops treatments targeting conditions like neurodegeneration and metabolic decline. In 2025, it will begin clinical trials for its ER-100 therapy. This drug uses partial epigenetic reprogramming to restore vision in age-related eye diseases.

Earlier tests in primates showed no tumor growth. The company is also exploring lipid nanoparticle delivery methods—similar to COVID-19 mRNA vaccines—and partners with research labs worldwide.

Other notable players are rising fast.

Rubedo Life Sciences is testing RLS-1496, a compound that clears aging cells. The drug enters Phase 1 trials in the Netherlands in 2025.

TROIL develops consumer anti-aging products using Meta-Cleanse™ technology. Over 85% of users reported improved health markers.

Insilico Medicine, backed by a $1.2 billion deal with Sanofi, uses AI to design drugs and tools to measure biological age.

Retro Biosciences is raising $1 billion to extend lifespan by 10 years. Its research includes autophagy enhancement and cellular reprogramming.

Billionaires like Jeff Bezos and Sam Altman have invested in Altos Labs and Retro. Governments in Hong Kong, Singapore, and Israel are also backing longevity research.

Research Focus, Funding Rounds, and Product Pipelines

Longevity startups are pouring billions into reversing or slowing aging. Their focus ranges from cell rejuvenation to gene therapy and metabolic health.

Altos Labs raised $3 billion to explore reprogramming cells back to a younger state using tools like Yamanaka factors. Its team includes Nobel laureates and leaders in gene editing and epigenetics.

Calico Life Sciences, with $1.5 billion in backing, partners with AbbVie in a joint program for drug development. It applies AI to health data and works on predictive models of biological aging. Calico also designs new small-molecule drugs with Terray Therapeutics.

Life Biosciences is testing ER-100 in human trials starting in 2025. Early work in primates showed promise without tumors. Its pipeline includes therapies for the eyes, brain, and muscles, delivered via lipid nanoparticles.

New Limit, founded by Coinbase CEO Brian Armstrong, raised $40 million to pursue epigenetic reprogramming. It targets gene expression rather than the genetic code and remains in stealth mode.

Rejuvenate Bio doubled the lifespan of mice using gene therapy. It now prepares for human studies, with a pipeline focused on heart disease and muscle loss.

BioAge Labs raised $170 million to target metabolic and immune aging. Its lead programs focus on inflammation and muscle atrophy. It uses AI to mine human data for targets.

Other players include Rubedo Life Sciences and TROIL. Rubedo’s senolytic drug RLS-1496 enters trials in 2025. TROIL markets consumer products with strong user-reported outcomes.

Retro Biosciences, backed by Sam Altman, works on autophagy, reprogramming, and plasma-based therapies. Insilico Medicine partners with Sanofi and builds aging clocks to track treatment response.

The longevity biotech sector raised over $5 billion in 2022. By 2025, the market for aging-related health solutions could reach $600 billion.

Challenges Faced by Early-Stage Biotech (R&D Timelines, Regulatory Hurdles)

Longevity biotech startups face a long and costly road to market. On average, drug approval takes 12 years and costs around $1 billion. These timelines stretch investor patience and burn through funding.

Early-stage companies often face project complexity. Fewer than 25% of major biotech efforts stay on schedule or budget. Shifting priorities and unclear milestones delay progress.

Funding is another hurdle. While the U.S. biotech sector raised $44.5 billion in 2024, early-stage companies received only about $36 million on average. Competition for capital is intense.

Regulatory barriers also loom large. The FDA does not classify aging as a disease. This forces companies to target specific conditions like Alzheimer’s or cancer to justify trials.

Permitting delays are costly. Regulatory expenses grew from $6.5 billion in 2016 to $20.8 billion in 2022. Local permit issues can stall trials for months or longer.

Global operations add complexity. Each country has different rules. Delays in one market can affect partnerships and timelines in others.

Talent is scarce. The surge in new startups has made experienced scientists and regulatory experts harder to hire. This slows development and stresses small teams.

Still, the field is expanding. Startups like Bioptimus have raised over €32 million for AI-driven drug discovery. Firms that align with broader trends—like digital health or sustainability—may find more support.

Investment & Funding Landscape

Leading Venture Capitalists, Private Equity, and Philanthropic Funding

Money is pouring into the longevity space from all corners—venture capital, private equity, and philanthropy.

Venture firms are leading the charge. LifeX VC manages $100 million for early-stage biotech. LongeVC and Longevity Vision Fund focus exclusively on companies targeting healthspan. LEAPS by Bayer has committed $1.5 billion to aging and regenerative medicine.

Altos Labs, backed by Jeff Bezos, raised $3 billion to reprogram cells and delay aging. Sam Altman put $180 million into Retro Biosciences, aiming to add 10 healthy years to the average lifespan. Peter Thiel supports the Methuselah Foundation, which invests in organ preservation and Alzheimer’s solutions.

BioAge Labs raised $170 million in early 2024 and plans a $142.5 million IPO. Alzheon secured $100 million for Alzheimer’s treatments. Aeovian Pharmaceuticals brought in $50 million to fight rare age-related diseases. These investments fuel therapies that aim to slow biological aging, not just treat symptoms.

Clinique La Prairie launched a fund to support companies blending wellness and science. L'Oréal invested in Timeline Nutrition to improve mitochondrial health. Its product, Mitopure, shows promise in restoring energy production in aging cells.

Philanthropic capital plays a growing role. The Hevolution Foundation pledged up to $1 billion annually to fund healthspan research. The Methuselah Foundation has funded nine companies working on regenerative technologies.

Nonprofits are stepping up, even with limited resources. The Longevity Science Foundation plans to raise $250,000 for fertility and women’s health. The Rainwater Charitable Foundation committed $2 million to fight neurodegenerative diseases like PSP.

However, less than 2% of philanthropic giving supports aging-related work. This is striking, given that aging contributes to two-thirds of all deaths globally. The need for aligned funding—across private, public, and nonprofit sources—is urgent.

As of 2025, over 75 longevity companies have raised $12.5 billion since 2015. The sector is expected to grow from $78.4 billion in 2024 to $376.5 billion by 2032.

Billionaires Backing Longevity (e.g., Jeff Bezos, Peter Thiel) and Their Motives

Billionaires are betting big on outliving biology. Jeff Bezos, Peter Thiel, and Sam Altman are among the most visible names funding the science of slowing—or even reversing—aging.

Bezos invested in Altos Labs, which employs leading scientists like Nobel laureate Shinya Yamanaka. Its mission is to reset cells to a younger state and delay the onset of age-related diseases.

Thiel has backed the Methuselah Foundation. The foundation aims to “make 90 the new 50” by 2030 and supports technologies like organ preservation and Alzheimer’s therapies.

Altman has committed $180 million to Retro Biosciences. The company focuses on cellular reprogramming, plasma exchange, and autophagy.

Other tech leaders are investing personally. Bryan Johnson spends about $2 million per year on his own body, tracking and optimizing everything from sleep to blood chemistry.

These billionaires share a core belief—that aging is not inevitable, but solvable. Some want to extend their own lifespans. Others aim to build the next trillion-dollar industry.

Their money shapes public conversations and attracts researchers to the field. Their interest helps aging move from fringe science to mainstream biotech.

Trends in IPOs, M&A, and Public Market Performance of Longevity Companies

Initial public offerings (IPOs) are rising in the longevity space. BioAge Labs plans to raise $142.5 million through a Nasdaq IPO after a $170 million Series D round.

Other firms are preparing to go public to fund trials and scale their platforms. Alzheon raised $100 million. Aeovian Pharmaceuticals raised $50 million for drugs targeting rare age-related diseases.

Mergers and acquisitions (M&A) have become a key growth strategy. In 2024, total M&A activity in life sciences reached $163 billion, up from $135 billion in 2023. Giants like Johnson & Johnson and Eli Lilly acquired smaller firms to expand their aging-focused pipelines.

Abacus Global Management reported $111.92 million in revenue from mergers alone. This reflects strong appetite for consolidation in therapeutics, diagnostics, and biotech tools tied to aging.

Public markets have taken notice. Health tech stocks rose 12% in 2024. AI-related longevity startups accounted for 38% of healthcare venture funding. These companies target diagnostics, early detection, and personalized treatment.

Investors now see aging not just as a medical issue, but as a financial opportunity. The sector is valued at $25 billion and expected to climb to $376.5 billion by 2032.

Still, the path to commercialization remains slow. FDA approvals often take 12 years for drugs and up to 7 years for devices. These hurdles impact valuations and delay returns.

Industry Collaborations & Rivalries

Strategic Alliances Among Startups, Pharma, and Academic Institutions

Longevity startups are not working alone. They are forming alliances with pharmaceutical giants, universities, and even beauty brands. These partnerships are shaping the future of aging science.

In December 2024, BioAge Labs and Novartis launched a joint research program. They committed $20 million upfront, with potential payouts of over $530 million. Their goal: use decades of human aging data to discover new drugs for age-related diseases.

Rubedo Life Sciences partnered with Beiersdorf AG, the skincare company behind Nivea. They’re developing senolytic products that clear aging cells from skin and plan to test these compounds in consumer products before clinical trials.

Other industries are joining the race too. Estée Lauder opened a BioTech Hub in Belgium in 2025 to replace synthetic ingredients with bioengineered molecules. Their aim is to align luxury beauty with longevity science.

AI is also driving new alliances. OpenAI joined forces with Retro Biosciences to use cellular reprogramming tools enhanced by machine learning. They aim to add 10 extra healthy years to human life.

Academic and nonprofit groups are central players. The nonprofit Hevolution Foundation has over $100 million committed to healthspan research. It funds 150 labs and supports 200 researchers worldwide.

In the UAE, NYU Abu Dhabi and the HealthX Accelerator have teamed up with the local government to back startups in health and aging. Since 2021, they’ve helped launch 80 companies and created nearly 1,000 jobs in the life sciences sector.

Large conferences now connect researchers, startups, and investors. The Aging Research and Drug Discovery (ARDD) Meeting in Copenhagen attracts major players like Lilly and Novartis. In London, the Founders Longevity Forum in June 2025 will showcase new collaborations and fund ventures.

Even hospitals and local governments are getting involved. Arca AI partnered with Believers Church Medical College Hospital and Longevity India to build aging health profiles and apply AI to track how people age over time.

Patent Landscapes, Licensing Deals, and Joint Ventures

The longevity sector is a race to patent the future. In the U.S., over 600 patents have been filed for cognitive enhancement wearables. Europe holds 500, and Asia-Pacific follows with 450. EEG headbands and brain-sensing devices lead the pack with more than 700 patents combined.

Surgical robotics also plays a role. Companies like Intuitive Surgical hold over 3,000 U.S. patents. These innovations support healthier aging through precision tools and miniaturized systems.

In therapeutics, startups are licensing technologies from top institutions. Turn Biotechnologies licensed ARMMs tech from Harvard for $300 million to deliver reprogramming molecules into aging cells.

MaxScientific partnered with Seragon Biosciences to improve Revigorator, its NAD+ booster. The new version aims for better absorption and effectiveness.

AI is reshaping drug development. Insilico Medicine raised $110 million for its pipeline. Its lead candidate, Rentosertib, treats age-related illnesses. Insilico also collaborates with Menarini Group on oncology drugs.

Joint ventures are emerging beyond biotech. The Estate plans to open 10 wellness resorts by 2030, blending health services with luxury tourism and charging members $35,000 annually.

Government funding continues to flow. In 2023, the U.S. NIH committed $6.4 billion to aging research—double the 2016 budget. These funds support gene therapy, regenerative medicine, and clinical research.

Consumer-facing startups are also drawing capital. OneSkin raised $20 million to reduce the biological age of skin. CytoMed Therapeutics acquired a Malaysian cord blood bank to support its regenerative therapy pipeline.

Meanwhile, Junevity raised $10 million for its RESET platform, which targets chronic diseases like Type 2 diabetes by improving glucose control without weight gain.

How Competition Is Driving Innovation—And Potential Duplication of Efforts

The longevity race is heating up. More than 554 teams are competing in the $101 million XPRIZE Healthspan Initiative, testing ways to extend healthy life. Ideas range from AI-driven diagnostics to stem cell therapies.

Events like the Healthy Longevity Global Grand Challenge and the Global Summit on Healthy Longevity attract thousands of scientists and entrepreneurs. These gatherings fuel competition and push teams to deliver faster, cheaper, and more effective solutions.

This race has led to breakthroughs. Integrated Biosciences raised $17.2 million to develop anti-aging drugs using synthetic biology and AI. Other companies are targeting gene therapies, biomarkers, or cellular reprogramming.

But the rush to innovate also brings risk. With hundreds of labs working on similar problems, duplication is a concern. In Alzheimer’s research, 132 papers by a prominent NIH scientist are under review for possible falsification—raising questions about repeated flawed findings.

Some companies compete on the same targets. Multiple startups pursue NAD+ boosters or senolytics. Many are developing skincare lines or glucose-control therapies for aging populations. In a market chasing patents and press, parallel pipelines are hard to avoid.

Regulators add pressure. Drug development takes up to 12 years and costs over $2.8 billion. With long approval timelines, companies rush to secure intellectual property and investor trust early—often before fully validating their science.

Still, competition has benefits. Awards like the NAM Catalyst offer $50,000 grants to smaller teams for new ideas. These competitions unlock talent from underfunded regions and drive global participation.

We don’t take shortcuts, chase headlines, or push narratives. We just bring you the news, straight and fair. If you value that, click here to become a paid subscriber—your support makes all the difference.

Table of Contents

(Click on any section to start reading it)

Introduction & Foundations of Aging

1. Setting the Stage

   • The grand vision for extending lifespan and healthspan

   • Why is there a “longevity race” now?

2. Historical Perspectives on Aging

   • Early theories and how understanding has evolved

   • Key milestones in gerontology and age-related research

3. Biology of Aging

   • Hallmarks of aging (cellular senescence, telomere attrition, DNA damage)

   • Role of genetics, epigenetics, and environment in aging

Core Interventions – From Caloric Restriction to Epigenetic Reprogramming

1. Caloric Restriction & Dietary Approaches

   • The science behind calorie restriction, intermittent fasting

   • CR mimetics (e.g., resveratrol, rapalogs)

   • Practical applications, controversies, and current clinical evidence

2. Epigenetic Reprogramming

   • Introduction to epigenetics and Yamanaka factors

   • Reversal of cellular aging in model organisms and early human trials

   • Opportunities, risks, and the path to translational therapies

3. Pharmacological & Supplement Strategies

   • Emerging anti-aging compounds (metformin, rapamycin, NMN)

   • Nutraceuticals and their scientific support

   • Off-label uses vs. formal drug development pipelines

The Billion-Dollar Ecosystem & Key Players

1. Biotech Startups in the Longevity Space

   • Profiles of high-profile startups (e.g., Altos Labs, Calico, Life Biosciences)

   • Research focus, funding rounds, and product pipelines

   • Challenges faced by early-stage biotech (R&D timelines, regulatory hurdles)

2. Investment & Funding Landscape

   • Leading venture capitalists, private equity, and philanthropic funding

   • Billionaires backing longevity (e.g., Jeff Bezos, Peter Thiel) and their motives

   • Trends in IPOs, M&A, and public market performance of longevity companies

3. Industry Collaborations & Rivalries

   • Strategic alliances among startups, pharma, and academic institutions

   • Patent landscapes, licensing deals, and joint ventures

   • How competition is driving innovation—and potential duplication of efforts

Societal Impact & Ethical Considerations

1. Moral & Philosophical Questions

   • Is aging a disease that should be cured, or a natural process?

   • Implications of radically extending human lifespans

   • Quality of life vs. longevity trade-offs

2. Social & Economic Ramifications

   • Potential strains on healthcare systems, pensions, and social security

   • Intergenerational equity and shifting demographic structures

   • Wealth disparities in accessing longevity therapies

3. The Global Perspective

   • Cultural attitudes toward aging across different regions

   • Health disparities: Will new therapies exacerbate or reduce them?

   • Possible worldwide collaboration or discord over extended lifespans

Policy & Regulatory Landscape

1. Aging as a Disease?

   • Current regulatory status and debates on classifying aging

   • Approaches by FDA, EMA, and other global regulatory bodies

   • Implications for clinical trials, reimbursement, and patient access

2. Intellectual Property & Patent Strategies

   • Unique challenges in patenting longevity therapies

   • IP battles and how they shape innovation

   • Licensing, open-source biology, and collaborative frameworks

3. Policy Proposals & Government Initiatives

   • Public-private partnerships for anti-aging research

   • Proposed legislation and funding programs

   • Future directions: Encouraging or hindering longevity innovation?

The Road Ahead – Emerging Technologies

1. Next-Gen Therapeutics & Technology

   • Gene editing (CRISPR/Cas9) for senescence and rejuvenation

   • AI-driven drug discovery for personalized anti-aging therapies

   • Organ regeneration, tissue engineering, and other moonshots

2. Predictions & Future Scenarios

   • Short-, medium-, and long-term outlook for practical breakthroughs

   • Potential game-changers—where could the field be in 10–20 years?

   • Risks of hype vs. realistic timelines

Baked with love,

Anna Eisenberg ❤️